Trade-Ideas LLC identified

Inovio Pharmaceuticals

(

INO

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Inovio Pharmaceuticals as such a stock due to the following factors:

  • INO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.6 million.
  • INO traded 217,759 shares today in the pre-market hours as of 8:19 AM, representing 10.3% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in INO with the Ticky from Trade-Ideas. See the FREE profile for INO NOW at Trade-Ideas

More details on INO:

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Currently there are 5 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Inovio Pharmaceuticals has been 1.2 million shares per day over the past 30 days. Inovio has a market cap of $378.2 million and is part of the health care sector and drugs industry. The stock has a beta of 2.75 and a short float of 22.2% with 6.29 days to cover. Shares are down 22% year-to-date as of the close of trading on Wednesday.

TheStreet Recommends

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Inovio Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • The gross profit margin for INOVIO PHARMACEUTICALS INC is rather low; currently it is at 17.48%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, INO's net profit margin of 23.13% is significantly lower than the industry average.
  • INO's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 41.58%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, INOVIO PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • INO has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 9.94, which clearly demonstrates the ability to cover short-term cash needs.
  • Net operating cash flow has significantly increased by 291.78% to $15.43 million when compared to the same quarter last year. In addition, INOVIO PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of 0.88%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.